A New Horizon of Hope for ALS Treatment
The World's First※
Treg Therapy for ALS
Harnessing the body's own immune system to help regulate excessive inflammation
We offer a new option to help slow the progression of ALS.
※ As of April 20, 2026, based on a review conducted by Medical Corporation Keijinkai of publicly available information on the internet, no reports were identified describing the use of a three-agent combination therapy consisting of Treg cells, CTLA4-Ig, and low-dose IL-2 as an established clinical treatment for patients with amyotrophic lateral sclerosis (ALS).
ALS & Treatment Videos
View All Videos
About Amyotrophic Lateral Sclerosis (ALS)
An overview of amyotrophic lateral sclerosis (ALS), an intractable disease, and the mechanisms of sustained neuroinflammation.
About Treg Therapy
The safety of Treg therapy using the patient's own cells and the features of the world's first combination therapy.
Clinical Support
Comprehensive support for patients and their families, from pre-treatment assessments through ongoing monitoring of treatment progress.
Q&A
Frequently Asked Questions
Find answers to common questions about treatment costs, duration of treatment, concomitant use with other medications, and receiving care while traveling from outside the local area.
View FAQs
EVIDENCE
Clinical Evidence
Access expert Q&A supported by scientific and clinical evidence, including research summaries, downloadable publications, and clinical trial data.
View Expert Q&A